A blog about what is new (and old) in the world of active implantable medical devices 

Facebook Twitter Gplus Flickr LinkedIn YouTube RSS
magnify
Home AIMD Business St. Jude Q2 2013 AIMD Results: CRM Down 4%, Neuromodulation 2% Up
formats

St. Jude Q2 2013 AIMD Results: CRM Down 4%, Neuromodulation 2% Up

logo_StJudeMedical

From today’s press release:

Cardiac Rhythm Management (CRM)

Total CRM sales, which include implantable cardioverter defibrillator (ICD) and pacemaker products, were $718 million for the second quarter of 2013, a 4 percent decrease compared to the second quarter of 2012. After adjusting for the impact of foreign currency, total CRM sales decreased 2 percent.

Of that total, ICD product sales were $454 million in the second quarter, a 1 percent decrease compared to the second quarter of 2012. ICD revenue was flat after adjusting for the impact of foreign currency.

Second quarter pacemaker sales were $264 million, an 8 percent decrease compared to the second quarter of 2012. On a currency neutral basis, pacemaker revenue declined 6 percent.”

“Neuromodulation

St. Jude Medical sales of neuromodulation products were $108 million in the second quarter of 2013, up approximately 2 percent from the prior year.”

 

 

 
 Share on Facebook Share on Twitter Share on Reddit Share on LinkedIn
Comments Off on St. Jude Q2 2013 AIMD Results: CRM Down 4%, Neuromodulation 2% Up  comments